Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.

International journal of cancer - 1 Aug 2025

Yoon Seug Yun, Yoon Sung-Soo, Yang Deok-Hwan, Lee Gyeong-Won, Sohn Sang Kyun, Shin Ho-Jin, Bae Sung Hwa, Choi Chul Won, Choi Eun-Ji, Cheong June-Won, Bang Soo-Mee, Park Joon Seong, Oh Suk Joong, Park Yong, Park Young Hoon, Lee Sung-Eun

Abstract excerpt

To prevent thrombosis in patients with polycythemia vera (PV), achieving a complete hematologic response (CHR) is highly recommended in practice. In addition, a reduced JAK2 V617F mutation burden is expected to have a disease-modifying effect, and its molecular response (MR) is currently of significant interest. This study aimed to assess the association between CHR and MR in patients with PV following treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Janus Kinase 2

Share to Polycythemia Vera

Share to Polyethylene Glycols

Share to Recombinant Proteins

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 40087986
DOI: 10.1002/ijc.35411
PMCID: PMC12141981

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.PMID 40087986Read ↗

Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.Semantic proximity Read ↗

Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.Semantic proximity Read ↗

[Sustained hematologic complete response after discontinuation of ropeginterferon alfa-2b in patients with polycythemia vera].Semantic proximity Read ↗

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.Semantic proximity Read ↗

Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera TreatmentSemantic proximity Read ↗

Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms.Semantic proximity Read ↗

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.Semantic proximity Read ↗

Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study.Semantic proximity Read ↗

Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.Semantic proximity Read ↗

The advantages and risks of ruxolitinib for the treatment of polycythemia vera.Semantic proximity Read ↗

Real-life use of ropeg-interferon α2b in Polycythemia Vera: patient selection and clinical outcomesSemantic proximity Read ↗

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.